GlassScriptPhysician profile
James L Mugford
NPI 1760582019
$11,813.42
in general payments reported to CMS, 2019-2025
35 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,795 · 2020: $1,261 · 2021: $1,805 · 2022: $1,466 · 2023: $1,972 · 2024: $1,841 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,487.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,301.73 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $1,274.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,141.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,125.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $835.17 | 2019-2025 | Jardiance, Spiriva Respimat |
| Glaxosmithkline, LLC. | $662.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $588.09 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $503.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $488.36 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Exact Sciences Corporation | $403.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $360.30 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $353.24 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $293.34 | 2019-2023 | |
| Astellas Pharma US INC | $280.38 | 2019-2025 | Veozah |
| Abbvie INC. | $239.57 | 2021-2023 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mugford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.